Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis.
暂无分享,去创建一个
Jeffrey Wyckoff | Erik Sahai | John Condeelis | E. Sahai | J. Segall | J. Condeelis | J. Wyckoff | Jeffrey E Segall | Mazen Sidani | C. Xue | F. Liang | M. Sidani | S. Violini | Kun-Lin Tsai | Zhonghua Zhang | Chengsen Xue | Fubo Liang | Stefania Violini | Kun-Lin Tsai | Zhong-Yin Zhang | Chengsen Xue
[1] Rakesh K. Kumar,et al. Enhanced production of an EGF-like growth factor by parenchymal macrophages following bleomycin-induced pulmonary injury. , 1997, Experimental lung research.
[2] R. Twombly. Failing survival advantage in crucial trial, future of Iressa is in jeopardy. , 2005, Journal of the National Cancer Institute.
[3] A. Agarwal,et al. Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3'-kinase and phospholipase C-dependent mechanism. , 1999, Cancer research.
[4] Amanda Y. Chan,et al. EGF stimulates lamellipod extension in metastatic mammary adenocarcinoma cells by an actin-dependent mechanism , 2004, Clinical & Experimental Metastasis.
[5] J. Segall,et al. A critical step in metastasis: in vivo analysis of intravasation at the primary tumor. , 2000, Cancer research.
[6] E. Sherwood,et al. Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate , 2004, World Journal of Urology.
[7] J. Segall,et al. The collection of the motile population of cells from a living tumor. , 2000, Cancer research.
[8] A. Wells,et al. Cell movement elicited by epidermal growth factor receptor requires kinase and autophosphorylation but is separable from mitogenesis , 1994, The Journal of cell biology.
[9] J. Pollard,et al. A Paracrine Loop between Tumor Cells and Macrophages Is Required for Tumor Cell Migration in Mammary Tumors , 2004, Cancer Research.
[10] G. Hortobagyi,et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. , 2004, Cancer cell.
[11] Sam A. Johnson,et al. Kinomics: methods for deciphering the kinome , 2004, Nature Methods.
[12] J. Zavadil,et al. Single cell behavior in metastatic primary mammary tumors correlated with gene expression patterns revealed by molecular profiling. , 2002, Cancer research.
[13] J. Segall,et al. Intravital imaging of cell movement in tumours , 2003, Nature Reviews Cancer.
[14] G P Nolan,et al. High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. , 1998, Cancer research.
[15] E. Bongcam-Rudloff,et al. Cell scattering and migration induced by autocrine transforming growth factor alpha in human glioma cells in vitro. , 1997, Cancer research.
[16] I. Fidler,et al. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.
[17] R. Dickson,et al. EGF receptor expression, regulation, and function in breast cancer , 2004, Breast Cancer Research and Treatment.
[18] A. Wells,et al. Epidermal growth factor receptor-mediated cell motility: phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement , 1994, The Journal of cell biology.
[19] N. Haites,et al. Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704. , 1996, European journal of cancer.
[20] Philip Chen,et al. EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells , 1996, Clinical & Experimental Metastasis.
[21] John S. Condeelis,et al. Identification and Testing of a Gene Expression Signature of Invasive Carcinoma Cells within Primary Mammary Tumors , 2004, Cancer Research.
[22] O. Skalli,et al. TGF-alpha differentially regulates GFAP, vimentin, and nestin gene expression in U-373 MG glioblastoma cells: correlation with cell shape and motility. , 2000, Experimental cell research.
[23] N. Normanno,et al. Small Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: An Overview , 2004, Journal of chemotherapy.
[24] S. Kohno,et al. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. , 2005, Cancer research.
[25] L. Lillien,et al. EGFRs mediate chemotactic migration in the developing telencephalon. , 2001, Development.
[26] G. Ferns,et al. EGF mediates monocyte chemotaxis and macrophage proliferation and EGF receptor is expressed in atherosclerotic plaques. , 2004, Atherosclerosis.
[27] M. Klagsbrun,et al. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF , 1991, Science.
[28] A. Kakita,et al. Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients , 2002, Molecular Psychiatry.
[29] M. Klagsbrun,et al. The Epidermal Growth Factor Receptor Couples Transforming Growth Factor-α, Heparin-binding Epidermal Growth Factor-like Factor, and Amphiregulin to Neu, ErbB-3, and ErbB-4* , 1996, The Journal of Biological Chemistry.
[30] E. Rosen,et al. Protein factors which regulate cell motility , 1989, In Vitro Cellular & Developmental Biology.
[31] H. Kaneto,et al. Selective Induction of Heparin-binding Epidermal Growth Factor-like Growth Factor by Methylglyoxal and 3-Deoxyglucosone in Rat Aortic Smooth Muscle Cells , 1997, The Journal of Biological Chemistry.
[32] G. Kéri,et al. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). , 2005, Cancer research.
[33] J. Segall,et al. Imaging of cancer invasion and metastasis using green fluorescent protein. , 2000, European journal of cancer.
[34] A. Levitzki,et al. Tyrosine kinase inhibition: an approach to drug development. , 1995, Science.
[35] J. Segall,et al. Epidermal growth factor receptor distribution during chemotactic responses. , 2000, Molecular biology of the cell.
[36] J. Segall,et al. Lamellipodia in invasion. , 2001, Seminars in cancer biology.
[37] G. Nicolson,et al. Development and biologic properties of malignant cell sublines and clones of a spontaneously metastasizing rat mammary adenocarcinoma. , 1982, Journal of the National Cancer Institute.
[38] Erik Sahai,et al. Tumor cells caught in the act of invading: their strategy for enhanced cell motility. , 2005, Trends in cell biology.
[39] A. Wells,et al. Tumor invasion: role of growth factor-induced cell motility. , 2000, Advances in cancer research.
[40] C. J. Barnes,et al. The Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 (Iressa) Suppresses c-Src and Pak1 Pathways and Invasiveness of Human Cancer Cells , 2004, Clinical Cancer Research.
[41] J. Foekens,et al. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: Results of a 10 year follow-up study , 2004, Breast Cancer Research and Treatment.
[42] M Hosokawa,et al. Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth. , 1996, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[43] Paul M. Schneider,et al. High-Throughput Analysis of Genome-Wide Receptor Tyrosine Kinase Expression in Human Cancers Identifies Potential Novel Drug Targets , 2004, Clinical Cancer Research.
[44] E. Neilson,et al. The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. , 2003, Cancer research.
[45] T. Mcclanahan,et al. Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.
[46] C. J. Barnes,et al. Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets , 2003, Cancer and Metastasis Reviews.
[47] F. Kirchhoff,et al. Epidermal Growth Factor is a Motility Factor for Microglial Cells In Vitro: Evidence for EGF Receptor Expression , 1997, The European journal of neuroscience.
[48] György Kéri,et al. Cellular targets of gefitinib. , 2005, Cancer research.
[49] M. Meyerson,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.
[50] K. Gibson,et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. , 2002, Cancer research.